Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Trastuzumab (Herceptin)].

Yutaka Tokuda¹, Yasuhiro Suzuki, Yuuki Saitou

¹Department of Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy

|April 30, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.

Anticancer research·2022

Same author

The association of <i>ACTN3</i> R577X polymorphism with sports specificity in Japanese elite athletes.

Biology of sport·2022

Same author

Effects of Branched-Chain Amino Acids on Skeletal Muscle, Glycemic Control, and Neuropsychological Performance in Elderly Persons with Type 2 Diabetes Mellitus: An Exploratory Randomized Controlled Trial.

Nutrients·2022

Same author

Marked Reduction of Cerebral Vasospasm with Intrathecal Urokinase Infusion Therapy after Endovascular Coil Embolization of the Aneurysmal Subarachnoid Hemorrhage: A Case Series.

Neurologia medico-chirurgica·2022

Same author

Antemortem Diagnosis of Pulmonary Tumor Thrombotic Microangiopathy in a Patient with Recurrent Breast Cancer: An Autopsy Case Report.

The Tokai journal of experimental and clinical medicine·2022

Same author

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).

Cancer science·2022

Trastuzumab, an anti-HER 2 antibody, shows efficacy in metastatic breast cancer, alone or with paclitaxel. Careful monitoring is needed due to potential cardiotoxicity, especially with prior anthracycline use.

Area of Science:

Oncology
Immunotherapy
Molecular Biology

Context:

HER 2/neu gene overexpression in various cancers.
Trastuzumab (Herceptin) is a humanized monoclonal antibody targeting HER 2/neu.
Clinical availability in Japan since June 2001 for metastatic breast cancer.

Purpose:

Review the basic and clinical data of trastuzumab.
Evaluate its efficacy and toxicity in cancer therapy.
Discuss its role as a molecular target for antibody therapy.

Summary:

Trastuzumab targets HER 2/neu, a protein overexpressed in certain cancers.
Clinical studies demonstrate efficacy in metastatic breast cancer, both as monotherapy and in combination with paclitaxel.
Identified toxicities include infusion reactions and cardiotoxicity, necessitating cautious use, particularly in patients with prior anthracycline exposure.

Related Experiment Videos

Impact:

Provides a comprehensive overview of trastuzumab for clinicians and researchers.
Highlights the therapeutic potential and safety considerations of HER 2/neu targeted therapy.
Informs clinical decision-making regarding trastuzumab use in breast cancer treatment.